The failure of axons in the central nervous system (CNS) to regenerate has been considered the main factor limiting recovery from spinal cord injury (SCI). Impressive gains in identification of growth-inhibitory molecules in the CNS led to expectations that their neutralization would lead to functional regeneration. However, results of therapeutic approaches based on this assumption have been mixed. Recent data suggest that neurons differ in their ability to regenerate through similar extracellular environments, and moreover, they undergo a developmental loss of intrinsic regenerative ability. Factors mediating these intrinsic regenerative abilities include expression of (1) receptors for inhibitory molecules such as the myelin-associated growth inhibitors and developmental guidance molecules, (2) surface molecules that permit axon adhesion to cells in the path of growth, (3) cytoskeletal proteins that mediate the mechanics of axon growth, and (4) molecules in the intracellular signaling cascades that mediate responses to chemoattractive and chemorepulsive cues. In contrast to axon development, regeneration might involve internal protrusive forces generated by microtubules, either through their own elongation or by transporting other cytoskeletal elements such as neurofilaments into the axon tip. Because of the complexity of the regenerative program, one approach will probably be insufficient to achieve functional restoration of neuronal circuits. Combination treatments will be increasingly prominent. SCI is a debilitating and costly condition that compromises pursuit of activities usually associated with an independent and productive lifestyle. This article discusses recent advances in neurorehabilitation that can improve the life quality of individuals with SCI.
Introduction
There are approximately 250,000 people with spinal cord injury (SCI) in the United States, and 16% of those are veterans.
1 SCI remaining function. 2 This first part of this article focuses on how advances in understanding the factors that modulate axon regrowth can be translated into clinical treatments and how technology can enhance the functional ability of individuals after SCI. 3 The second part focuses on recent advances in neurorehabilitation that can improve the life quality of individuals with SCI. 2 The Clinical Trials Guidelines Panel of the International Campaign for Cures of Spinal Cord Injury Paralysis has published a series of guidelines to encourage clinical studies of spinal cord regeneration protocols. [4] [5] [6] [7] The North American Clinical Trials Network for the Treatment of Spinal Cord Injury was established to facilitate patient recruitment into SCI treatment protocols. That network is collecting data on the natural history of SCI. Then the group will form a clinical trials network to study proposed treatments. As a result of these and several other initiatives, the translation from basic research to clinical applications should be accelerating.
Loss of function with SCI results from interruption of axonal connections and from the death of neurons. When an axon is transected, the portion that becomes detached from the cell body degenerates (Wallerian degeneration). The proximal portion retracts, and the neuron, now deprived of its normal synaptic targets, is vulnerable to retrograde death by apoptosis. However, if the neuron survives, its axon may regenerate. Axon regeneration is common in peripheral nerves but is more problematic in the spinal cord. Understanding the environmental factors that limit regeneration in the spinal cord and the intraneuronal determinants of axon regeneration in the central nervous system (CNS) should ultimately help us attain functional regeneration after human CNS injury.
Attempts of CNS axons to regenerate after axon injury are partially suppressed by inhibitory signals in the injured axon tip. The ability of CNS axons to grow for long distances into peripheral nerve grafts inserted into the spinal cord shows that CNS axons can regrow into a permissive environment 8 and suggests that factors in the extracellular environment of the CNS contribute to failure of axon regeneration. CNS myelin contains proteins that block axon growth. 9 Removing myelin promotes regeneration. 10 However, the most profound effects of treatments aimed at removing myelin-associated growth inhibitors may be in enhancing the sprouting of uninjured axons after partial SCIs. 11 Another regeneration barrier is the glial scar that forms after CNS injury. Inhibitory proteins consisting mainly of proteoglycans, secreted by reactive astrocytes, contribute to the scar barrier. 12 Application of chondroitinase ABC, which digests chondroitin sulfate proteoglycans, enhances axon regeneration and functional recovery after SCI. 13 
Fetal Tissue Environments Support Axonal Growth Better than Mature Tissue
During development, axons elongate by a process that involves advance of a specialized structure at the leading edge, the growth cone, which adheres to the extracellular matrix, advances by polymerization of actin at its distal end, and uses an actin-myosin molecular motor to pull the axon along. Growth cone motility is influenced by the interactions between humoral agents and axonal receptors such as the Nogo receptor (NgR), which binds myelinassociated growth-inhibitory proteins; the Trk family of receptors, which bind neurotrophins and some other growth factors; and guidance molecule receptors (Fig. 1 ). These receptors trigger intracellular signaling at the level of the growth cone and retrogradely into the cell body.
Regeneration of spinal cord axons is possible if either environmental or intracellular growthinhibiting influences can be neutralized. An important caveat in interpreting results on the basis of the actions of molecular agents on growth cone motility is that it is not clear that regeneration of axons in the mature CNS Figure 1 . Extracellular humoral influences on the growth cone. Many substances exert positive or negative influences on the growth cone by binding to specific surface receptors and activating intracellular signaling pathways that lead to advance or retraction of the growth cone. Many of these signals act by activating the polymerization or depolymerization of F-actin in the filopodia and lamellipodium. Some of these molecular influences include neurotrophins (NT), which bind to receptors of the tyrosine kinase (Trk) family. At least three myelin-associated molecules cause growth cone collapse by binding to the Nogo receptor (NgR). Cytokines (Ck) released by nonneuronal cells at the site of an injury bind to cytokine receptors (CkR) and may excite or inhibit growth. Several molecules that guide the growing axons during development are expressed in the mature CNS and may attract (Gme) or repel (Gmi) growing axons by binding to their respective receptors (GmeR and GmiR). Growth enhancement and inhibition are indicated by + and −, respectively. Modified from McKerracher and Selzer. 3 involves growth cones at all. In the lamprey, where spinal axons regenerate spontaneously, the axon tips appear to lack the morphological and cytoskeletal features of true growth cones. 14 Analogous observations have not been made in other species. Thus, the significance of growth cone-collapsing molecules in limiting regeneration in the CNS is not clear.
In culture, primary embryonic neurons grow axons much faster than neurons from older animals. 15 Although axons of dorsal root ganglion (DRG) cells maintain their ability to grow into adulthood, there is a simplification, loss of F-actin staining and slower growth for growth cones of DRG neurons cultured from older [embryonic day 14 (E14)] than for younger (E7) chick embryos. 16 In early postnatal mammals compared with adults, axons more readily regenerate into and through fetal spinal cord grafts and mediate functional recovery. 17 In addition to the inhibitory molecular environment for regeneration in the mature CNS, as neurons mature, they become intrinsically less able to regenerate their axon. Experiments with dissociated neurons microinjected into adult CNS suggested that embryonic neurons can send out long axons when transplanted into myelinated axon tracts in several regions. 18 However, except for DRG neurons microinjected into the spinal cord, 19 this approach has not worked with dissociated adult neurons.
Another factor that modulates recovery after injury is the heterogeneity of the ability of axons from different neurons to regenerate. In mammals, growth into peripheral nerve grafts varies. Some neurons (e.g., those of the thalamic reticular nucleus, substantia nigra pars compacta, and deep cerebellar nuclei) regenerate axons robustly, whereas others (e.g., thalamocortical projection neurons, striatal projection neurons, and cerebellar Purkinje cells) regenerate poorly. 20 Studies of chronic SCI show that even long-injured axons can regenerate if appropriately simulated.
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Neuronal Response Depends on Injury Site
One puzzling observation on regenerative potential is that the distance of the axonal injury from the perikaryon has a large effect on axon regrowth and cell survival. In neurons of the lamprey brain and spinal cord, axotomy near the cell body results in sprouting of long axonlike neurites from the dendritic tree rather than from the cut axon tip. 22 Similarly, distal dendrites of neck motor neurons in adult cats can give rise to an axonlike process that expresses GAP43. 23 The site of axotomy also affects neuronal survival. Axotomy near the cell body is correlated with better regeneration into peripheral nerve grafts 24 and upregulation of GAP43, a molecule that is believed to be involved in axon growth. 25 Observations about neuronal death can be difficult to interpret. Rat rubrospinal neurons thought to be dead 1 year after axotomy in the cervical spinal cord regenerated into peripheral nerve grafts after application of growth factors. 26 However, other studies indicate that close axotomy can lead to cell death. 27 Therefore, there is both cell death and neuronal atrophy after axotomy, and these encouraging results show that rescue of atrophied neurons is possible.
A prerequisite for axon regeneration is that the injured neuron survive; however, enhanced survival does not portend enhanced regrowth. For example, neurotrophins both promote cell survival and stimulate neurite outgrowth for embryonic neurons placed in culture. In the adult CNS, there is a clear separation between survival and regeneration. More retinal ganglion cells survive axotomy than can extend axons in peripheral nerve grafts. 28 In transgenic mice that overexpress the antiapoptotic gene, bcl-2, more retinal ganglion cells survive optic nerve injury, but there is no enhancement in growth into peripheral nerve grafts.
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Extrinsic Molecular Signaling of Axon Injury
The external environment greatly influences intrinsic growth ability of an injured neuron. Figure 2 summarizes some known extracellular signals, and their effect on the cytoskeletal dynamics, which in turn control the axonal motility and axonal transport that underlie axon regeneration. Figure 2 . ROCK and Rho. The growth-inhibiting effects of several molecules, including the myelinassociated growth inhibitors, converge on a common signaling mechanism that involves activation of Rho GTPases and their activation of ROCK, which leads to complex downstream effects, including the depolymerization of F-actin. At least three receptor molecules are probably involved cooperatively in this process: Lingo, NgR, and the low-affinity neurotrophin receptor p75. 107 The intracellular domain of p75 binds to the Rho-GDP dissociation inhibitor (GDI), 108 thus allowing dissociation of GDP from Rho, which is then activated by binding GTP. Intracellular cAMP translocates Rho from the membrane, resulting in transient local effects to maintain growth cone motility. More important, cAMP activity works through transcriptional mechanisms to activate growth-promoting pathways. 92 Modified from McKerracher and Selzer. 3 
Cytokines
After axonal injury in vivo, the inflammatory response includes production of both beneficial and detrimental cytokines. 30 Inflammation near rat DRG cells enhances regeneration of their central axons. 31 Macrophages stimulated by exposure to peripheral nerve promoted the clearance of myelin and regeneration of injured axons, whereas macrophages exposed to CNS myelin did not. 32 Macrophages exposed to peripheral nerve delivered to a spinal cord site of injury led to partial motor recovery in paraplegic rats, 33 which formed the basis of a phase I clinical trial (safety and feasibility; Proneuron Biotechnologies) in human spinal cord-injured patients. Autologous macrophages were activated by coincubation with the patients' own skin and then injected into the spinal cord just caudal to the injury. 34 The effect on recovery is not known because the clinical trial was suspended for financial reasons. Interleukin 6 is upregulated by manipulations that increase cyclic AMP (cAMP) activity in DRG cells and may represent one of several pathways by which cAMP enhances regeneration. 35 Neuropoietic cytokines bind to the gp130 receptor, which has several intracellular effects, including activation of the transcription factor STAT3 (signal transducer and activator of transcription). Activation of STAT3 enhanced regeneration of DRG axons in vitro, whereas activation of the STAT3 inhibitor SOCS3 (suppressor of cytokine signaling) inhibited axon regeneration. 36 Thus, the STAT3 pathway appears to mediate at least some of the regeneration-enhancing effects of cytokines, presumably by transcriptional mechanisms.
Inflammation can also be destructive. Inflammation after injury evolves with time and causes secondary damage when invading inflammatory cells destroy injured tissue and contribute to necrosis. 37 Within hours of SCI, elevated levels of a proinflammatory cytokine, tumor necrosis factor (TNF), are expressed by activated microglia, monocytes, and reactive astrocytes. 30 Cytokines and chemokines expressed by microglia signal invasion of hematogenous cells that express additional cytokines and chemokines. 38 Activated TNF receptor activates a GTPase, Rho, 39 which blocks axon growth. 40 Strategies to reduce inflammation include the application of anti-integrin antibody to suppress the invasion of hematogenous macrophages, 41 neutralization of the Fas receptor that is expressed by injured cells in the CNS, 42 and neutralization of the T-lymphocyte chemoattractant CXCL10. 43 The purported neuroprotective and regeneration-promoting effects of skin activation of macrophages could be due to a reduction in their secretion of TNF-α and an increase in their secretion of the growth-enhancing cytokine interleukin 1β. 44 Cerebrospinal fluid drainage has improved outcome in ischemic injuries of the spinal cord, 45 perhaps owing to removal of toxic cytokines. After ischemic injuries in rodent brain, there is extensive axon sprouting and reorganization of local anatomical connections in the periinfarct area. 46 The endogenous expression of the cytokine/erythrocyte-trophic molecule erythropoietin may mediate axon sprouting and reorganization, which may contribute to the spontaneous recovery after ischemia. 47 The synthetic tetracycline antibiotic minocycline reduced severity of SCI. 48 It appears to reduce axon retraction and apoptotic cell death of oligodendrocytes, possibly by inhibiting several aspects of the inflammatory response through inhibition of the p38 mitogen-activated protein kinase pathway, a regulator of immune cell function and cell death. 49 A phase I clinical trial is under way. 50 
Neurotrophins
Neurotrophins are peptide molecules that act on cells through specific receptors that activate intracellular signaling mechanisms to promote cell differentiation and survival. 51 Low levels of trophic factors are important in maintaining the integrity of neurons. Neurons obtain some of their trophic support from the target tissues to which their axons project. After axotomy, neuronal survival and regenerative sprouting can be enhanced by supplying neurotrophins exogenously. Each type of neuron has its own requirement for a specific trophic factor or combination of factors. Other manipulations, such as fetal tissue transplants 21 or antibodies to Nogo, can enhance the effect of neurotrophins. 52 Intrathecal application of nerve growth factor, neurotrophin 3, or glial cell-derived neurotrophic factor enables the crushed central axons of DRG cells, which ordinarily do not regenerate, to regrow into the spinal cord, form functional synapses with neurons in the dorsal horn, and even partially reestablish sensory function. 53 Elevation of intracellular cAMP levels and consequent activation of protein kinase A (PKA) partly mediates the effects of neurotrophins in enhancing axonal regeneration. 54 
Excitotoxins
Release of the excitatory transmitter glutamate after CNS trauma results in the death of exposed neurons that express glutamate receptors (excitotoxicity). Blocking N -methyl-Daspartate receptors can prevent cell death after neurotrauma. 55 Oligodendrocytes are also vulnerable to glutamate toxicity, possibly involving AMPA receptors. 56 Growth cones exposed to excessive excitotoxins are susceptible to growth cone collapse from elevated calcium levels, which disassembles the actin cytoskeleton. Calcium transients are important in the regulation of axon growth, and either too much or too little can arrest growth cone extension. Glutamate added to neurons in culture can enhance rates of neurite outgrowth, 57 and glutamate can help steer axon turning. 58 A phase II clinical trial of an N -methyl-D-aspartate antagonist, GK-11, to limit excitotoxic damage in acute SCI is currently under way (Neureva, France).
Myelin-associated Growth Inhibitors
The best-characterized growth-inhibitory molecules are concentrated in myelin: myelinassociated glycoprotein (MAG), 59 Nogo, 60 and OMgP. 61 A receptor that binds Nogo has been identified as the Nogo-66 receptor. 62 Surprisingly, MAG and OMgP also bind to the NgR. Thus, all the myelin-associated growthinhibitory proteins share a common signaling pathway in neurons. 61, 62 Other inhibitory proteins such as proteoglycans are expressed by cells that form the lesion scar.
Most human SCIs are partial; therefore, experimental models of partial SCIs are relevant and form the bulk of experimental work in this field. The two most widely used models are the contusion injury produced by weight drop, 63 which mimics the pathology in most human SCIs, and the dorsal overhemisection, 64 which severs the main corticospinal tract in rodents. Tracer is injected into the motor cortex and is transported anterogradely to label the regenerating axons. On the basis of these types of models, it was claimed that neutralizing Nogo with antibodies, either alone or with other treatments, could induce regeneration of corticospinal axons. 9 However, experiments in Nogo-deficient mice and in mice deficient in the Nogo receptor showed conflicting results with some studies suggesting that these mice show regeneration of corticospinal tract axons, 65 whereas other studies found no effect. 66 It has now been conceded that the corticospinal tract axons do not regenerate, although raphespinal and rubrospinal axons can. 67 Part of the difficulty in interpreting the results of therapeutic manipulations in partial-injury models of SCI is that eliminating that collateral sprouting of spared axons is impossible. Indeed, enhanced collateral sprouting by unlesioned corticospinal tract axons has been demonstrated by experiments in which pyramidotomy eliminated the corticospinal projection on one side of the cord and anterograde tracing labeled the crossing sprouts.
11 Similar difficulties limit interpretation of anterograde label demonstrations of axon regrowth in partial-injury models after other treatments, such as RhoA inhibitors, enhancement of cAMP activity, or chondroitinase digestion of chondroitin sulfate proteoglycans.
Despite the preceding limitations, a phase I open-label clinical trial of intrathecal infusion of anti-Nogo antibodies for treatment of SCI (Martin Schwab, principal investigator, Novartis) is being carried out in Europe, and thus far there has been no indication of significant toxicity. Therefore, a larger and randomized controlled trial is planned for North America. Another approach to neutralizing the NgR has been developed using the recombinant form of the extracellular portion of NgR [NgR(310)ecto-Fc]. This protein binds and inactivates all three myelinassociated growth-inhibitory proteins. Experiments in rats have suggested that intrathecal infusion of NgR(310)ecto-Fc may increase sprouting of raphespinal and corticospinal axons and promote functional recovery after spinal cord contusion. 68 Growth-inhibitory proteins signal growth cone collapse by affecting intracellular signalling cascades. One component of the cascade is the small intracellular GTPase Rho, which is activated by growth-inhibitory proteins. 69 Rho activation prevents regeneration and contributes to apoptotic cell death. 70 Another key signaling molecule is cAMP. Elevation of cAMP can override the inhibitory response to NgR signaling. 54 The cAMP response element binding (CREB) protein activates genes involved in axon growth. At the local level, single filopodial contact of growth cones with growth-inhibitory proteins cause growth cone turning, 71 whereas contact with larger quantities causes the collapse of the growth cone and retraction of the neurite. Time-lapse studies suggest that axons may attempt to grow around a growthinhibitory contact, such as an oligodendrocyte, but repeated contacts lead to failed neurite growth. 72 Many strategies have been devised to circumvent growth-inhibitory influences for axon regeneration in the spinal cord. One strategy is the introduction of axon-supporting cells, that is, Schwann cells and olfactory ensheathing glia. Schwann cells have repeatedly shown promise for remyelination, support of axon regeneration, and functional recovery, 63 but thus far, these cells have not been used in humans. There are contradictory reports of the benefits of olfactory ensheathing glia for promoting functional recovery after SCI in animals. 73, 74 Methodological differences may explain some of the discrepancies. Nevertheless, olfactory ensheathing cells grown from nasal biopsy samples have been transplanted in hundreds of paraplegic/tetraplegic patients in China. Despite claims of improvement in some patients, these reports have been criticized for lack of control subjects. A small-scale phase I controlled clinical trial has begun in Australia. 75 Embryonic stem cells or oligodendrocyte progenitors can be induced to become oligodendrocytes in vivo and have remyelinated axons and promoted functional recovery when transplanted into injured spinal cords. 76, 77 Embryonic human oligodendrocyte precursors will soon be tested in a phase I clinical trial.
The potassium channel blocker 4-amino pyridine can improve the excitability of demyelinated axons. In partially demyelinated axons, exposed paranodal potassium channels can make conduction slow or insecure. By blocking the potassium channels, 4-aminopyridine might recover axon electrical function. 78 A small-scale clinical trial has suggested safety and efficacy. 79 However, two phase III clinical trials (Fampridine-SR, Acorda, and HP-184, Sanofi-Aventis) failed to document substantial benefits for functional recovery. 80 
Intrinsic Signaling of Axon Injury
Calcium
Calcium is an intracellular signal in growth cone guidance. Local elevation in axoplasmic calcium concentration can trigger the rapid formation of a growth cone. 81 Once formed, however, transient elevations of intracellular calcium in filopodia at sites of clusters of integrin molecules inhibit the motility of the growth cone. 82 Inhibitory guidance molecules such as semaphorins and netrins also cause local elevations in intracellular calcium by activating L-type voltage-dependent calcium channels.
Rho GTPases
Rho GTPases are a family of highly related proteins that are best characterized for their effect on the actin cytoskeleton. They also have a key role in regulating the neuronal response to growth-inhibitory proteins. The major members of the Rho family include Rho, Rac, and Cdc42. Rho inactivation prevents growth cone collapse and promotes neurite growth on myelin. 83 Inactivation of either Rho or Rho kinase promotes neurite growth on proteoglycan substrates that model inhibitory proteins of the glial scar. 84 Inactivation of Rho allows axons to grow past an astrocyte/meningeal scar. 85 Rho also regulates the neuronal response to chemorepulsive factors. 86 Rho is activated after SCI and p75, a receptor that signals apoptosis of damaged neurons, is upregulated. 70 Reversal of Rho activation was cell protective. 87 Rho can be inactivated via ADP ribosylation by C3 transferase, a bacterial endotoxin. 88 Rho kinase (p160ROCK) is a downstream effector activated by Rho. After SCI, inactivation of Rho with C3, or of ROCK with Y-27632 or fasudil, promoted axon regeneration and functional recovery. 89 Extradural application of a cell-permeable form of C3, BA-210 (BioAxone Therapeutic; licensed to Alseres Pharmaceuticals), administered at the time of surgical decompression has completed a phase I/II open-label clinical trial without evidence of serious toxicity. 90 A larger randomized controlled study is planned.
cAMP
The effects of neurotrophic factors, guidance molecules, and myelin-associated growth inhibitors depend on the levels of cAMP. High cAMP levels produce chemoattraction of growth cones, and low levels promote chemorepulsion. 54 Sometimes the effects of cGMP are the opposite of those of cAMP. Netrin can be chemoattractive or chemorepellent, on the basis of the receptor complex with which it interacts and on the intraneuronal ratio of cAMP to cGMP, a high ratio favoring chemoattraction. Cyclic nucleotides modulate the activity of Ltype calcium channels consistently with their effect on growth cone guidance. 91 SCI reduces neuronal cAMP levels. 63 Raising cAMP levels in vivo overcomes growth inhibition and promotes regeneration after SCI in rats. 63 Injury-induced reduction in cAMP levels was prevented by administration of the phosphodiesterase IV inhibitor rolipram to rats with spinal cord contusions, while also injecting db-cAMP near the injury raised cAMP levels above normal. When these two treatments were combined with transplants of Schwann cells into the injury, each treatment enhanced axonal regeneration and functional improvement, and the combination was more effective than any one element alone. 63 Taken together, the emerging studies suggest that cAMP prepares the neuron for a regenerative response. The short-term effects of cAMP involve local actions within the growth cone, including neutralization of Rho by translocating it away from the cell membrane. However, transcriptional mechanisms, mediated via PKA activation of CREB, primarily mediate the long-term growth-promoting effects of cAMP. 92 
Transcription Factors
Transcription factors are central to any coordinated molecular program, and several transcription factors are upregulated after axotomy and during axonal regeneration, including members of the Jun and Fos families, components of the transcription factor AP-1. Transgenic mice lacking the c-jun gene in the CNS showed deficient regeneration and sprouting of motor axons, atrophy of motoneurons, and failure of upregulation of several other regeneration-associated molecules such as CD-44. 93 Expression of CREB is associated with physiological and anatomical plasticity in neurons. Given the importance of cAMP to axon growth, one might expect CREB to participate in axon regeneration. There is evidence that cAMP, working through PKA and CREB, activates genes that neutralize the growth-inhibiting effects of the myelinassociated growth-inhibiting molecules, such as MAG. However, because it is not clear to what degree growth cone collapse is a limiting factor in CNS axon regeneration, perhaps transcriptional effects of CREB include other growthpromoting pathways.
The immediate early gene nuclear factor κB (NF-κB) exists in all cell types and has been implicated in the early control of the neuronal response to injury and regeneration. NF-κB is present in the cytoplasm in an inactive form bound to its inhibitor IκB. Upon stimulation by an extracellular signal, NF-κB is released from its inhibitor, translocates to the nucleus, and participates in many regulatory processes. NF-κB is activated as early as 30 min after CNS injury, is still present at 72 h, and is expressed by both macrophages/microglia and neurons. 30 Activation of NF-κB in neurons is a response to proinflammatory cytokines that are elevated after injury and might be related to the apoptotic death of neurons that is part of the secondary inflammatory response. NF-κB is also activated during the excitotoxin-induced apoptosis of striatal neurons 94 and can be activated by Rho, 95 raising the possibility that abnormal Rho activation after SCI activates NF-κB and leads to neuronal death. 70 
Intrinsic Determinants of Regeneration
After CNS injury, growth cones form at the tips of cut axons. Damaged axons do not regenerate significant distances when the balance between positive and negative growth cues is unfavorable. Thus, although many studies show that blocking growth-inhibiting molecules can promote regeneration in the injured spinal cord, axons do not typically grow farther than 1 cm. Many neurons have long axons, which depend on the transport of substances from the cell body for their nourishment, a function performed by the microtubules. Pathological processes that interrupt axonal transport will interrupt regeneration, although in the short run, growth cone motility can occur even in axon segments separated from the cell body.
During development, the growing tips of axons display growth cones, consisting of filopodia and lamellipodia. These adhere to extracellular substrata and contain surface receptors for guidance and adhesion molecules that translate surface binding into intracellular signals serving many functions, including axon elongation and turning, as well as inhibition of axon growth. Filopodia contain F-actin and elongate by polymerization of actin microfilaments at their distal (+) ends. Lamellipodia contain actin, myosin, and microtubules but do not contain neurofilaments. Filopodia and lamellipodia might exert tension on the axon through interactions among actin, myosin, and the microtubules, thus pulling the axon forward. 96 The fastest growth seems to be associated with lamellipodial action, 15 whereas filopodia are believed to be important in axon pathfinding and turning. 97 Microtubules and actin participate in growth cone responses to guidance molecules. 98 A second axon lesion closer to the cell body than the first lesion accelerates the rate of regeneration after axonal injury. The demonstration that peripheral axotomy of DRG cells could promote subsequent regeneration of their central axons after dorsal column lesion in adult rats was an important insight into the increase in intrinsic growth state produced by conditioning lesions. 99 Although the precise mechanism is still incompletely understood, the conditioning lesion increases cAMP levels in the DRG. 100 
Growth-associated Proteins
A strategy to identify molecules that may participate in regeneration is protein electrophoresis on homogenates from nervous system tissues during regeneration of axons, followed by comparing the patterns of protein expression with that of the same tissue under control conditions. Several rapidly transported growth associated proteins have been identified. The bestknown growth-associated protein is the 43-kDa GAP43. 25 The precise function of this protein is not known, but it is associated with the growth cone membrane, is phosphorylated by PKC, and binds to calmodulin, inducing neurite sprouting and synaptic transmitter release. 101 GAP43 is expressed constitutively in neurons during axon development and then downregulated. However, not all axon growth involves GAP43. GAP43 is important in the generation of growth cones but is not sufficient to induce regeneration. However, when GAP43 and the 23-kDa cytoskeleton-associated protein (CAP23) were overexpressed together, DRG axons regenerated after spinal cord transection. 102 It was suggested that alone, GAP43 and CAP23 promote sprouting of the axon terminal by mobilizing subplasmalemmal actin accumulation but that the two must act together to promote longer-distance regeneration. Another GAP, small proline-rich repeat protein 1A (SPRRP1A), is upregulated in DRG cells after peripheral axotomy. In DRG cells in vitro, overexpression of SPRRP1A enhanced neurite outgrowth, even on inhibitory substrates, and colocalization of the protein with F-actin in the ruffles of growth cones, whereas blocking SPRRP1A function inhibited axon growth. 103 
Guidance Molecule Receptors
Of the molecules that have been identified as growth cone-collapsing factors, some are developmental guidance molecules, for example, netrins, semaphorins, and ephrins. These growth-inhibiting molecules will be effective only to the extent that axons bear receptors for them on their surfaces. Little is known about how expression of these receptors affects axon regeneration. In development, netrin exerts both chemoattractive and chemorepulsive effects. Semaphorins are almost exclusively growth-inhibitory molecules. After injuries in the CNS, fibroblasts of the glial scar express semaphorin III in the adult but not the neonatal rat. 104 In the rat spinal cord, injured corticospinal and rubrospinal tract axons express neuropilins and plexins, the receptors for semaphorins. 105 Thus, semaphorin signaling may contribute to failure of regeneration in the injured spinal cord.
NgR signals growth inhibition by myelinderived inhibitory proteins. 61 The level of expression of NgR by axons is probably a key determinant of regeneration because of its importance for signaling growth inhibition by MAG, OMgP, and Nogo. Whether there is widespread expression of NgR in the CNS has been controversial, but now different NgR homologues have been identified, and expression of NgR in the CNS appears to be widespread. 106 The signaling by NgR has been well studied, and NgR can modify the actin cytoskeleton through its activation of Rho. NgR lacks a cytoplasmic domain, and it forms a receptor complex with the p75 neurotrophin receptor and a protein called Lingo. 107, 108 When growth-inhibitory proteins activate the receptor complex, Rho is activated. 108 Plating neurons on growth-inhibitory substrates activates Rho, and this blocks axon growth. 89 
Cell Adhesion Molecules
Several strategies to promote regeneration involve transplantation of peripheral nerve grafts, Schwann cells, or other growthpromoting components of peripheral nerve, including fibroblasts genetically engineered to produce nerve growth factor. There is evidence that regeneration of CNS axons through these modified extracellular environments depends on the balance between permissive (e.g., laminin) and inhibitory (e.g., the chondroitin sulfate proteoglycan [CSPG]) extracellular matrix molecules associated with these grafts. 109 Therefore, the ability of neurons to express receptors or complementary binding molecules on their surface could be important intrinsic determinants of their intrinsic regenerative ability. Thus, the ability of axons to regenerate through peripheral nerve grafts in mammalian experimental models correlated with their expression of L1 110 and its close homologue CHL1. 111 In zebra fish, where axons regenerate spontaneously after spinal cord transection, the regenerative abilities of different supraspinal axon tracts correlated with the ability of their neurons to express the homophilic cell adhesion molecule L1 but not another homophilic member of the immunoglobulin G superfamily, NCAM. 112 Moreover, morpholinobased inhibition of L1.1 synthesis inhibited axon regeneration and locomotor recovery. 113 After SCI in adult rats, treatment with soluble L1-Fc promoted axon regeneration and functional recovery. 114 Thus, adhesion molecules can help overcome an inhibitory environment and favor axon regeneration. The growthinhibiting effects of CSPGs are not necessarily due to a growth cone-collapsing effect, as for the myelin-associated growth inhibitors that bind to the NgR. Instead, CSPGs appear to mask the receptor sites for binding of axons to growth-promoting extracellular adhesion molecules such as laminin. 115 Nevertheless, the signaling of axon growth inhibition by NgR agonists and CSPG may converge, because at least sometimes, inhibition of the Rho-ROCK pathway can neutralize the inhibitory effect of CSPG.
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Conclusions about Spinal Cord Regeneration
For more than 100 years, the failure of axons in the CNS to regenerate has been considered the main factor limiting recovery from neural injury. The impressive gains in identification of growth-inhibitory molecules in the CNS led to expectations that their neutralization would lead to functional regeneration. However, results of therapeutic approaches based on this assumption have been mixed. More recent data suggest that neurons differ in their ability to regenerate through similar extracellular environments, and moreover, they undergo a developmental loss of intrinsic regenerative ability. The factors mediating these intrinsic regenerative abilities include expression of (1) receptors for inhibitory molecules such as the myelin-associated growth inhibitors and developmental guidance molecules, (2) surface molecules that permit axon adhesion to cells in the path of growth, (3) cytoskeletal proteins that mediate the mechanics of axon growth, and (4) molecules in the intracellular signaling cascades that mediate responses to chemoattractive and chemorepulsive cues. The tendency for growth cones to simplify progressively during development, with a reduced reliance on actindriven growth cones, and the simple shapes of regenerating axon tips described in the lamprey and other animal models of CNS regeneration, suggest that axons may compensate for an abundance of inhibitory cues targeted at actin-based axon elongation by using a second mechanism of growth (Fig. 3) . In contrast to axon development, regeneration might involve internal protrusive forces generated by microtubules, either through their own elongation or by transporting other cytoskeletal elements such as neurofilaments into the axon tip. Because of the complexity of the regenerative program, one approach will probably not be sufficient to achieve functional restoration of neuronal circuits. Combination treatments will be increasingly prominent.
Finally, after many years of cautious experimentation, scientific advances have begun to justify translation to the clinic. At the same time, an infrastructure for ethical and efficient clinical trials in SCI repair is being established. And these advances in the laboratory and the clinical arena are being matched by applications of the principles of evidence-based medicine to physical therapeutic and other rehabilitative modalities, as well as by increasing sophistication in outcome measurement. Thus, we can be optimistic that translation of basic scientific discoveries into effective clinical treatments for SCI will accelerate in the coming decade.
What People with SCI Want in Terms of Motor Function
During the initial period of recovery after SCI, most people want return of motor function. After learning how to travel using assistive devices such as wheelchairs, the desires of people with SCI change. However, beyond the first year after injury, the ordering of desired return of function remains about the same.
116,117 Figure 4 shows the ordering of the first and second priorities for return of function among people with paraplegia or tetraplegia. The restoration of motor functions (hand use or walking) is an important priority for individuals with SCI.
Experimental Technology to Enhance
Motor Function of People with SCI Currently available treatment options for individuals with SCI often do not enable functional restoration of the necessary physiological function. Methods are inadequate to restore the ability to grasp and manipulate objects for persons with a tetraplegia level of C5-6, which is an important determinant of functional, independent, and societal participation. With limited or no hand function, individuals with midcervical injuries need to rely on specialized adaptive equipment or personal assistance to accomplish many essential self-care activities such as grooming, personal hygiene, and eating. The associated lack of elbow extension also restricts workspace to the area immediately in front of the body, compromises the ability to stabilize objects in space or control the trajectory of the hand, and often necessitates the use of two hands to accomplish tasks that could formerly be accomplished using only one hand. Such impairments are compounded in higher-level tetraplegia because paralysis of the proximal musculature compromises control of the entire arm and further affects functional independence. Thoracic-level SCI negatively affects the ability to exercise; sit stably; and perform many personal mobility activities including standing transfers, walking, and negotiating architectural barriers. An estimated one-third of all individuals with paraplegia require assistance with activities of daily living, community mobility, or essential transfers. 118 Although the wheelchair offers a means of Figure 3 . Hypothetical switch from actin-based to microtubule-based growth in regeneration of injured mature axons. Top: During development, there is a loss of intrinsic regenerative ability that is partially explained by a reduction in intraneuronal cAMP levels, which would thereby reduce the activation of PKA. It has been hypothesized that PKA inactivates Rho by phosphorylating it, thereby rendering the axon less susceptible to the effects of myelinassociated growth inhibitors and chemorepulsive guidance molecules. Thus the developmental changes, including a reduction in cAMP levels, lead to an increased sensitivity of the regenerating axon tip to several growth cone-collapsing influences in its extracellular environment. Bottom: Mature axons can regenerate despite the absence of a conventional growth cone. The residual growth may be due to internal protrusive forces generated by microtubules, either directly through their own elongation or indirectly through their transport of other cytoskeletal elements, such as neurofilaments. Modified from McKerracher and Selzer. at all levels can exact a toll on family members and other caregivers who are responsible for the physical assistance required to accomplish the most routine daily activities.
As stated earlier, priorities for people with SCI have been studied. Hand/arm function is the highest priority for motor system recovery in individuals with tetraplegia, and trunk stability and bladder/bowel control and sexual function are high priorities for all levels of SCI. Walking movement is highly rated, particularly for people with paraplegia. 116, 117 Walking in constrained or poorly accessible environments can be enabled by stand/transfer and swing-to gait systems.
Electrical activation of paralyzed musculature by using neuroprosthetics is among the most promising modalities to restore function in severely disabled individuals. Although neuroprostheses do not restore entirely normal movement, they restore function that cannot be obtained through any other means. Individuals with tetraplegia can gain control of grasp and release, enabling them to perform various activities of daily living, such as eating, drinking, and brushing teeth, as well as other tasks such as writing and taking money out of a wallet. [119] [120] [121] Individuals with SCIs can also gain control of bladder and bowel function, with a significant effect on quality of life. 122 Bowel care time can be significantly reduced and the rate of bladder infections can be decreased. 123 For individuals with high-level tetraplegia, phrenic pacing can replace dependence on a ventilator, considerably improving quality of life and respiratory health. 124, 125 Implanted neuroprosthetic systems, although initially expensive, are actually cost-effective over the lifetime of the disabled individual. 123 For individuals with paraplegia, neuroprosthetic systems can provide the ability to stand, enabling the individual to retrieve objects from shelves or to work at a counter. 126, 127 Also, the ability to stand can simplify transfers in and out of the wheelchair, reducing the strain on an attendant. Walking function has also been demonstrated, including the ability to go up and down steps. 128, 129 For individuals with hemiplegia due to stroke, electrical stimulation can be used as a hand neuroprosthesis to open and close the hand and allow completion of functional tasks such as feeding, grooming, dressing, and toileting. Similarly, a lower-limb neuroprosthesis may enhance overall mobility manifested by improved gait speed, symmetry, and balance and less dependence on assistive devices and compensatory strategies.
Brain-Computer Interface Technology
People who have tetraplegia due to high cervical spinal cord lesions or individuals with nerve root damage or motor neuron disease are poor candidates for electrical stimulation technology. Bridging the disconnection between brain and muscle requires interpreting brain activity and interfacing brain signals with a computer, that is, creating a brain-computer interface (BCI). Researchers have long sought ways of interpreting brain activity to drive devices that could restore function for individuals with conditions that disconnect the brain from the body. Several research teams are working on different ways to establish a BCI. We will discuss two promising approaches. This bold work demonstrated that the brain continues to generate signals that can be used to restore motor function even after injury to the pathways that connect the brain to limbs. 130 This research arose from successful collaboration among multiple universities, the Department of Veterans Affairs, the National Institutes of Health, and private industry.
One approach focuses primarily on noninvasive, electroencephalography (EEG)-based BCI methods. 131, 132 This system uses surfacerecorded EEG signals to move a cursor rapidly and accurately in one or two dimensions. A small electrode cap and standard EEG electrodes record EEG from the scalp. A laptop computer translates these signals into control of applications such as word processing, e-mail, Internet access, or use of any Windows-based computer program. This system also uses a robust visual-evoked EEG signal, the P300 wave, to allow a computer to recognize symbols such as letters that the user wishes to be identified. For example, by rapidly and repeatedly scanning the alphabet, a user can spell words that are recognized by the BCI to enable paralyzed, nonverbal subjects to communicate via e-mail, speech synthesizer, or other method. The advantages of this surface recorded EEG system are as follows: (1) it is noninvasive; (2) the technology is relatively inexpensive and easy to implement; (3) there is a rapid learning curve so that subjects can use the technology to communicate on the first or second trial; and (4) once the subject is set up with the EEG cap in place, the subject can use the BCI without additional support. The initial results from the first set of users indicate that the BCI system gives them an increased sense of independence and improves their quality of life. They use the BCI for a variety of communication purposes. One man runs his business by using BCI-based communication.
Another variant of BCI is more daring, with potentially more capability, but also using more complex and invasive technology that takes more time for the user to learn. 133 This second type of BCI system uses a 96-electrode array implanted on the surface of the brain, with electrodes projecting into the primary motor cortex, to record electrical activity. Cabling from the skull connects the electrodes to processing computers on a cart. The system enabled a man with tetraplegia due to SCI to control a computer, operate devices such as a television, control a prosthetic hand, and perform tasks with a multijointed robot. The level of control of the prosthetic arm was limited to simple positioning and opening and closing of the hand. The subject could operate devices while performing other activities (e.g., talking). The system responded to brain activity (albeit with eventual signal decrease) for the entire 9-month study. Limitations of the system include that the computer must learn to interpret the neuronal activity patterns of each subject and that the electrode array must be implanted on the brain surface. Also, this technology will need further refinement before it can be clinically implemented. If these findings can be replicated, this technology could permit thought control of devices by people with brain stem, spinal cord, or nerve root or peripheral nerve injury and by amputees.
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